Tamiflu (Oseltamivir) Dosing Recommendations
For adults and adolescents ≥13 years, the standard treatment dose is 75 mg orally twice daily for 5 days, initiated within 48 hours of symptom onset. 1, 2
Adult and Adolescent Dosing (≥13 years)
Treatment:
- 75 mg orally twice daily for 5 days 1, 3, 2
- Must be initiated within 48 hours of symptom onset for maximum effectiveness 1, 3
- Earlier initiation (within 12-24 hours) provides greater clinical benefit, reducing illness duration by an additional 53.9-74.6 hours compared to treatment started at 48 hours 4
Prophylaxis:
- 75 mg orally once daily 1, 3
- Post-exposure prophylaxis: 10 days following close contact with infected individual 1, 2
- Seasonal prophylaxis: Up to 6 weeks during community outbreak 2
- Immunocompromised patients: May continue up to 12 weeks 2
Pediatric Dosing (≥12 months)
Weight-based dosing for treatment (twice daily for 5 days): 1, 3, 2
- ≤15 kg (≤33 lb): 30 mg twice daily
- >15-23 kg (>33-51 lb): 45 mg twice daily
- >23-40 kg (>51-88 lb): 60 mg twice daily
- >40 kg (>88 lb): 75 mg twice daily
Prophylaxis dosing: Same weight-based doses but once daily for 10 days 1, 2
Infant Dosing (<12 months)
Term infants 0-8 months:
Infants 9-11 months:
Critical caveat: Prophylaxis is not recommended for infants <3 months unless the situation is judged critical due to limited safety data 1
Preterm Infant Dosing
Dosing based on postmenstrual age (gestational age + chronological age): 1, 3
- <38 weeks postmenstrual age: 1.0 mg/kg twice daily
- 38-40 weeks postmenstrual age: 1.5 mg/kg twice daily
- >40 weeks postmenstrual age: 3.0 mg/kg twice daily
This age-based adjustment is essential to avoid toxicity due to immature renal function in preterm infants 1, 3
Renal Impairment Adjustments
For creatinine clearance 10-30 mL/min: 1, 3
- Treatment: 75 mg once daily for 5 days (instead of twice daily)
- Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 doses total)
Dose adjustment is critical in renal insufficiency to prevent drug accumulation 1
Formulation and Administration
- Capsules: 30 mg, 45 mg, 75 mg
- Oral suspension: 6 mg/mL when reconstituted
Oral suspension dosing volumes: 1
- 30 mg dose = 5 mL
- 45 mg dose = 7.5 mL
- 60 mg dose = 10 mL
- 75 mg dose = 12.5 mL
Administration tips:
- Can be taken with or without food 1, 3, 2
- Taking with food significantly improves gastrointestinal tolerability, reducing nausea and vomiting (which occur in approximately 10-15% of patients) 1, 4, 5
- Capsules can be opened and contents mixed with liquid for patients unable to swallow capsules 1
- If commercial suspension unavailable, pharmacies can compound suspension from capsules to achieve 6 mg/mL concentration 1
Important Clinical Pearls
Timing is critical: Treatment efficacy is highly dependent on early initiation—within 48 hours of symptom onset for treatment, and within 48 hours of exposure for post-exposure prophylaxis 1, 3, 4
Drug interaction: Avoid live attenuated influenza vaccine (LAIV) within 48 hours before oseltamivir use, and do not use oseltamivir for 14 days after LAIV vaccination 1
Common adverse effects: Gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common, typically mild and transient, resolving within 1-2 days 1, 4